Detectie van tumorweefsel met behulp van Bevacizumab-IRDye800CW in combinatie met een optisch beeldvormingssysteem bij patiënten die de HIPEC procedure ondergaan, een haalbaarheidsstudie.

This project consist of the realization and clinical validation of intraoperative imaging of tumor tissue in peritoneal carcinomatosis of colorectal origin.
By applying a method to assess the extend of peritoneal dissemination of cancer through a novel targeted optical fluorescent imaging methodology staging and resection might be more optimal.

VEGF-A is highly unregulated in colorectal tumortissue and can be targeted by using the VEGF antibody Bevacizumab (Avastin). Bevacizumab can be conjugated to the near infrared fluorphore, 800CW (bevacizumab-IRDye800CW).

In this study 10 patients scheduled for a HIPEC procedure will receive an IV injection with bevacizumab-IRDye800CW two days prior to the procedure.

During the procedure fluorescent tissue will be sampled and will be analyzed by an pathologist. The peritoneal cancer index wil be estimated using the fluorescent signal.

All procedures will be carried out in the University Medical Center Groningen

day 1 tracer administration

day 3 operation date

Patients scheduled for a HIPEC procedure for peritoneal carcinomatosis of colorectal origin will be consented for this study. There will be three study related visits. During a screening visit (visit 1), eligibility will be evaluated and patient characteristics will be collected. During the second visit 4.5 mg of bevacizumab-­‐IRDye800CW will be administered intravenously. The patient will then be observed for 1 hour post administration. One day after administration of the tracer (visit 3 one day before surgery) the patient is administered to the hospital as in the standard procedure, or the patient can stay after the tracer injection if this more convenient for the patient. During the HIPEC procedure the fluorescent imaging will be performed and data acquired.